SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (107)6/13/2001 4:59:34 PM
From: tuck  Respond to of 1005
 
Peter,

Thanks. Hopefully stefaan can comment. My cut yesterday on PTIE's stock price near term is on so far:

>>. Until then, I expect it to retest its lows and then some.<<

On fairly light volume, it did exactly that today. Gonna load up? If you're right, the market, through exiting VC, is likely "offering to do" some "thing stupid." BLUE HP now considering a small position in case good data gets announced before the VC finish bailing.

Edit: Gadz, in two weeks this has dropped 30% on no news. Technically way oversold, but closed on its low. Nibbling in high 5s tomorrow.

siliconinvestor.com

ReEdit: Wow, not a good day for VGNX, either. That is looking silly cheap now. Much good commentary on VGNX by Rick et. al. on that thread:

Subject 50989

Cheers, Tuck



To: Biomaven who wrote (107)6/15/2001 4:16:10 PM
From: tuck  Respond to of 1005
 
Peter,

Stefaan's anesthesiologist friend suggests that the PTIE drug's mechanism at ultralow dose could be from sole stimulation of the kappa receptor, and that even if not approved by FDA it could be sellable in europe. FWIW.

Cheers, Tuck


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News